Latest Headlines

51. Nuclera And Cytiva Collaborate To Accelerate Characterization Of Proteins For Drug Development 5/28/2025

    Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery System, has announced a collaboration with Cytiva, a global life sciences leader.

52. Selvita Acquires License For Medicines Discovery Catapult's Patented Target Engagement Technology 5/27/2025

    Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.

53. GSK's Depemokimab Accepted For Review By Health Canada For The Treatment Of Asthma With Type 2 Inflammation And For Chronic Rhinosinusitis With Nasal Polyps 5/26/2025

    GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller.

54. Siegfried Expands Production Capacity For Ophthalmic Drugs In El Masnou 5/23/2025

    Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, today announced a further expansion of its ophthalmic drug manufacturing site in El Masnou near Barcelona, Spain.

55. Global Summit On Microphysiological Systems Research Set To Shape The Future Of Drug Development And Disease Modeling 5/22/2025

    The 4th Annual MPS World Summit, hosted by the International MPS Society (IMPSS) and supported by EUROoCS, will take place in Brussels, Belgium this summer.

56. Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-1418, A Potential Best-In-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate 5/22/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-1418 (DB-1418), a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC).

57. GATC Health Paper Quantifies AI-Driven Capital Efficiencies And Advances Human-Centered Drug Discovery 5/22/2025

    GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, has published a new paper, AI in Drug Development: Advancing Capital Efficiency, Reducing Animal Testing, and Driving Precision Medicine.

58. Sanofi To Acquire Vigil Neuroscience, Inc., Adding A New Investigational Medicine To Treat Alzheimer's Disease To The Neurology Pipeline 5/21/2025

    Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases.

59. Genetic Mutations In Potassium Ion Channel Target Of New Drug Development 5/21/2025

    Ion channels are involved in almost everything our bodies do, from regular heartbeats to muscle function to allowing communication within the body. When something goes awry in the ion channels, it can have devastating effects on the body.

60. Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-023 (ARTS-023), A Potential Best-In-Class, Novel CDK4 Selective Inhibitor 5/21/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-023 (formerly ARTS-023), a potential best-in-class, novel cyclin-dependent kinase 4 (CDK4) selective inhibitor.